Melasma like hyperpigmentation on face: A rare side effect of imatinib

Authors : Anusha Gupta, Anusha Gupta, Sunil Kumar, Sunil Kumar, Saurav Chaturvedi, Saurav Chaturvedi, Apoorva Nirmal, Apoorva Nirmal

DOI : 10.18231/2348-7240.2018.0019

Volume : 5

Issue : 2

Year : 0

Page No : 79-80

Imatinib mesylate is a cytotoxic agent that is used in chronic myeloid leukaemia. Common reported side effect is hypopigmentation; here we report a 48 year old female who developed hyperpigmentation as melasma on her face while taking imatinib mesylate in a dose of 400 mg daily for chronic myeloid leukaemia.

Keywords: Drug-induced pigmentation, Imatinib-mesylate, Melasma, Chronic myeloid leukemia.


Citation Data


Related Articles